US-based Stanford Medicine has entered into a partnership with Leadoptik to investigate artificial intelligence (AI)-enhanced optical imaging in lung biopsy procedures.
Leadoptik is a Silicon Valley company specialsing in real-time medical imaging.
Its collaboration with Stanford Medicine aims to enhance lesion assessment and biopsy accuracy through advanced high-resolution imaging techniques.
According to Leadoptik, lung cancer is the leading cause of cancer-related deaths globally, with early detection crucial for improving survival rates. Diagnosing small lung nodules remains challenging, often resulting in inconclusive biopsies.
Through the partnership, Leadoptik and Stanford Medicine seek to integrate optical imaging into biopsy processes to offer immediate insights and a better understanding of tissue structures. This integration could potentially lead to advancements in AI-driven analysis.
Leadoptik focuses on pioneering AI-enhanced optical imaging at biopsy points, combining high-resolution visualisation with analytics. The Last Inch Assessment (LIA) system developed by the firm aims to bridge diagnosis and therapy, thereby enhancing decision-making in interventional pulmonology.
The Interventional Pulmonology Program at Stanford Medicine will lead the technology evaluation for lung biopsies.
Stanford Medicine will examine how combining microstructural visualisation with AI-powered interpretation can refine sample collection and enhance patient outcomes.
This partnership intends to utilise detailed optical imaging data from real clinical settings to enhance diagnostic precision and foster intelligent decision-making based on image guidance.
Stanford Medicine interventional pulmonology director Harmeet Bedi said: “Stanford Medicine is committed to evaluating and advancing technologies that have the potential to transform patient care.
“This collaboration allows us to assess whether real-time optical imaging, paired with data-driven insights, can enhance lung cancer diagnostics and improve biopsy precision.”
Through this collaboration, Leadoptik aims to advance technology that delivers high-resolution, real-time visualisation directly to physicians. The collected imaging data will aid in refining advanced analytics applications, supporting the clinical adoption of intelligent imaging solutions.
Leadoptik CEO Reza Khorasaninejad said: “This partnership with Stanford marks an important step in further validating our unique real-time imaging and exploring how advanced image analysis can further support physicians.
“By combining cutting-edge imaging with emerging smart tools, we aim to improve the precision of lung biopsy procedures and enable more confident clinical decision-making.”
